Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. School of Medicine / 醫學系
  4. Diagnostic FDG and FDOPA positron emission tomography scans distinguish the genomic type and treatment outcome of neuroblastoma
 
  • Details

Diagnostic FDG and FDOPA positron emission tomography scans distinguish the genomic type and treatment outcome of neuroblastoma

Journal
Oncotarget
Journal Volume
7
Journal Issue
14
Pages
18774-18786
Date Issued
2016
Author(s)
Liu, Y.-L., Lu, M.-Y., Chang, H.-H., Lu, C.-C., Lin, D.-T., Jou, S.-T., Yang, Y.-L., Lee, Y.-L., Huang, S.-F., Jeng, Y.-M., Lee, H., Miser, J.S., Lin, K.-H., Liao, Y.-F., Hsu, W.-M., Tzen, K.-Y.
MENG-YAO LU  
HSIU-HAO CHANG  
CHING-CHU LU  
Lin D.-T.
SHIANN-TANG JOU  
YUNG-LI YANG  
Lee Y.-L.
Huang S.-F.
YUNG-MING JENG  
Lee H.
Miser J.S.
Lin K.-H.
Liao Y.-F.
WEN-MING HSU  
HSINYU LEE  
DOI
10.18632/oncotarget.7933
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84975495950&doi=10.18632%2foncotarget.7933&partnerID=40&md5=febab4d3cab273006c413ff4a43488d8
https://scholars.lib.ntu.edu.tw/handle/123456789/469979
Abstract
Neuroblastoma (NB) is a heterogeneous childhood cancer that requires multiple imaging modalities for accurate staging and surveillances. This study aims to investigate the utility of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) and 18F-fluoro-dihydroxyphenylalanine (FDOPA) in determining the prognosis of NB. During 2007-2014, forty-two NB patients (male:female, 28:14; median age, 2.0 years) undergoing paired FDG and FDOPA PET scans at diagnosis were evaluated for the maximum standardized uptake value (SUVmax) of FDG or FDOPA by the primary tumor. Patients with older age, advanced stages, or MYCN amplification showed higher FDG and lower FDOPA SUVmax (all P < 0.02). Receiver operating characteristics analysis identified FDG SUVmax ? 3.31 and FDOPA SUVmax < 4.12 as an ultra-high-risk feature (PET-UHR) that distinguished the most unfavorable genomic types, i.e. segmental chromosomal alterations and/or MYCN amplification, at a sensitivity of 81.3% (54.4%-96.0%) and a specificity of 93.3% (68.1%-99.8%). Considering with age, stage, MYCN status, and anatomical image-defined risk factor, PET-UHR was an independent predictor of inferior event-free survival (multivariate hazard ratio, 4.9 [1.9-30.1]; P = 0.012). Meanwhile, the ratio between FDG and FDOPA SUVmax (G:D) correlated positively with HK2 (Spearman's ρ = 0.86, P < 0.0001) and negatively with DDC (ρ = -0.58, P = 0.02) gene expression levels, which might suggest higher glycolytic activity and less catecholaminergic differentiation in NB tumors taking up higher FDG and lower FDOPA. In conclusion, the intensity of FDG and FDOPA uptake on diagnostic PET scans may predict the tumor behavior and complement the current risk stratification systems of NB.
SDGs

[SDGs]SDG3

Other Subjects
carboxylyase; fluorodeoxyglucose f 18; fluorodihydroxyphenylalanine f 18; radiopharmaceutical agent; unclassified drug; 6 fluorodopa f 18; DOPA; fluorodeoxyglucose f 18; radiopharmaceutical agent; age; Article; cancer prognosis; cancer staging; cancer survival; child; chromosome aberration; clinical article; correlational study; DDC gene; diagnostic test accuracy study; drug uptake; event free survival; female; gene amplification; genome; genotype; glycolysis; HK2 gene; human; male; maximum standardized uptake value; MYCN gene; neuroblastoma; overall survival; PET scanner; positron emission tomography; predictive value; receiver operating characteristic; risk factor; sensitivity and specificity; treatment outcome; tumor differentiation; analogs and derivatives; cohort analysis; diagnostic imaging; disease free survival; genetics; genomics; infant; metabolism; neuroblastoma; positron emission tomography; procedures; prognosis; treatment outcome; Cohort Studies; Dihydroxyphenylalanine; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Genomics; Humans; Infant; Male; Neuroblastoma; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Treatment Outcome
Publisher
Impact Journals LLC
Type
journal article

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science